Back to Agenda
Session 2B: Pharmacopoeias: Collaboration Across Borders
Session Chair(s)
Erin Wang, MS, RAC
Associate Consultant – Compendial Affairs, Global Quality Laboratory
Eli Lilly and Company, US, United States
Pharmacopeias are recognized sources of public standards for pharmaceutical products, ingredients, components, and agreed common practices. Compendial standards are typically comprised of test procedures and associated acceptance criteria. These standards are enforced by regulatory agencies, and are quality standards to be met by all manufacturers/applicants for certain territories. Companies that wish to market products globally must have a robust strategy for meeting compendial requirements for each market. Collaboration between regulators, industry, and pharmacopeias is crucial to ensure that these standards serve to benefit public health, both regionally and internationally. This session will provide an overview of the United States and European compendial science activities. The industry presentation will share experiences in managing public standard implementation globally. Panel discussion will allow participants to have deeper interactions with the speakers and the fellow participants.
Speaker(s)
USP Compendial Activites
Shawn Dressman, PhD
United States Pharmacopeia, United States
Vice President, Chemical Medicines, USP-NF
European Pharmacopoeia Overview (presentation will be delivered via webinar)
Michael Wierer, DrSc
European Directorate for the Quality of Medicines and HealthCare, France
Head, Biological Standardisation, OMCL Network, Blood Transfusion and Transplant
Compendial Affairs
Craig Hamilton, PhD
Eli Lilly and Company, United States
Director - Operational Excellence, Global Quality Laboratory
Compendial Affairs
Erin Wang, MS, RAC
Eli Lilly and Company, US, United States
Associate Consultant – Compendial Affairs, Global Quality Laboratory
Have an account?